News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Merck & Co., Inc. Buys Hanwha Drug-Marketing Rights for $720 Million
June 13, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
South Korea's Hanwha Chemical said on Monday it had won a license deal worth $720 million for its biosimilar product with Merck Sharp & Dohme Research Ltd, a subsidiary of U.S. drug firm Merck & Co.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Asia
Merck & Co.
MORE ON THIS TOPIC
Collaboration
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
March 5, 2026
·
1 min read
·
Tristan Manalac
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
·
2 min read
·
Tristan Manalac
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
March 4, 2026
·
2 min read
·
Tristan Manalac
